Skip Navigation
Skip to contents

JPMPH : Journal of Preventive Medicine and Public Health

OPEN ACCESS
SEARCH
Search

Articles

Page Path
HOME > Korean J Prev Med > Volume 25(1); 1992 > Article
Original Article Factors affecting the price-reduction rates among the insurance medicines.
Hyoung Joong Kim, Woo Hyun Cho, Han Joong Kim, Byung Yool Cheon
Journal of Preventive Medicine and Public Health 1992;25(1):64-72
DOI: https://doi.org/
  • 2,064 Views
  • 19 Download
  • 0 Crossref
  • 0 Scopus
1Ministry of Health and Social Affairs, Korea.
2Department of Preventive Medicine and Public Health, Yonsei University, College of Medicine, Korea.
3The Armed Forces Medical Command, Korea.

To provide the information necessary for the insurance medicine management plan, price discount rates among the insurance medicines were studied. A total of 2,107 items of insurance medicine of which prices were discounted via government inspections of real transactional process of insurance medicine were analysed. The conclusions are as follows; 1. Among the variables relevant to the characteristics of manufacturers, price discount rates of insurance medicines were statistically significant with production rankings of manufacturers, incorporation year, existence of investments by foreign corporation, existence of a research institute, and enrollment in the exchange. And among the variables relevant to the properties of medicines, the number of enrolled items which have the same components, classification, the date of new enrollment, the sales of items, and the number of raw materials in the items were statistically significant. 2. Stepwide multiple regression was done to identify the factors which affect the price discount rates of insurance medicines. The number of enrolled items which have the same components, production rankings of manufactures, classification number (medicines for function of tissue cells), incorporation year (1940-1949), existence of investments by foreign corporations, classification number (anti-germ medicines), number of raw materials in the items, the sales of items, and medicines whose major objective is not treatment were significant variables and the R2-value for these variables was 21.2%. Considering all of the above results, for management of insurance medicines, it seems important that the real transactional prices of insurance medicines should be identified systematically, focusing on the properties which affect the price discount rates of insurance medicines.

Related articles

JPMPH : Journal of Preventive Medicine and Public Health